A comparative study of metabolic and hormonal effects of myoinositol vs. metformin in women with polycystic ovary syndrome: a randomised controlled trial

Riju Angik, Shubhada S. Jajoo, C. Hariharan, Amogh Chimote

Abstract


Background: The purpose of the study was to find out which drug is more effective in treatment and improvement of metabolic and hormonal parameters in women with polycystic ovary syndrome (PCOS); Myoinositol or Metformin. This study was conducted since there are very limited studies on the same.

Methods: Patients between 15-40 years of age with signs and symptoms of PCOS who attended the outpatient department of obstetrics and gynaecolgy at AVBRH between study period of September, 2012 to August 2014, were subjected to specific investigations to diagnose PCOS. Patients who were diagnosed with PCOS according to the Rotterdam criteria were included in the study group. Patients were randomly allocated to treatment with either myoinositol or metformin. Myoinositol group received 1 g twice daily while Metformin group received 500 mg twice daily for 6 months .The findings and investigations were repeated after 6 months and was compared with the baseline values.

Results: Treatment with myoinositol and metformin both decreased body mass index, androgenic features, improved menstrual abnormalities and polycystic ovaries but the Level of insulin resistance as measured by fasting insulin and homeostatic model assessment (HOMA) decreased only on treatment with myoinositol.

Conclusions: Myoinositol acts at the level of insulin receptors and is effective in treatment of hyperinsulinemia and insulin resistance, which is the underlying factor leading to the development of polycystic ovary syndrome.


Keywords


Polycystic ovary syndrome (PCOS), Myoinositol, Metformin, Insulin resistance, Homeostatic model assessment (HOMA)

Full Text:

PDF

References


Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434-8.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Task force on the phenotype of the polycystic ovary syndrome of the androgen excess and PCOS society. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456-88.

Fauser B, Taratzis B, Chang J, Aziz R. ESHRE/ASRM-Consensus document on polycystic ovary syndrome. Fertil Steril. 2004;18:19-25.

Vincenzo De Leo, Maria Concetta Musacchio, Valentina Cappelli, Alessandra Di Sabatino, Claudia Tosti, Paola Piomboni Leo, et al. A combined treatment with myo-inositol and monacolin k improve the androgen and lipid profiles of insulin-resistant PCOS patients. J Metabolic Synd. 2013;2:2.

Zacchè MM, Caputo L, Filippis S, Zacche G, Dindelli M, Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynaecol Endocrinol. 2009 Aug;25(8):508-13.

Kai I. Cheang, Jessica M. Huszar, Al M. Best, Susmeeta Sharma, Paulina A. Essah, John E. Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. Nestler Diab Vasc Dis Res. 2009 Apr;6(2):110-9.

Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009;13:105-10.

Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynaecol Endocrinol. 2013 Apr;29(4):375-9.

Marzieh Farimani Sanoee, Nosrat Neghab, Soghra Rabiee, Iraj Amiri. Metformin therapy decreases hyperandrogenism and ovarian volume in women with polycystic ovary syndrome. Iran J Med Sci. 2011 Jun;36(2):90-5.